PatientsVille.com Logo

VISION BLURRED and Penicillin

PatientsVille

VISION BLURRED Symptoms and Causes

What is high blood pressure in pregnancy?

Blood pressure is the force of your blood pushing against the walls of your arteries as your heart pumps blood. High blood pressure, or hypertension, is when this force against your artery walls is too high. There are different types of high blood pressure in pregnancy:

  • Gestational hypertension is high blood pressure that you develop while you are pregnant. It starts after you are 20 weeks pregnant. You usually don't have any other symptoms. In many cases, it does not harm you or your baby, and it goes away within 12 weeks after childbirth. But it does raise your risk of high blood pressure in the future. It sometimes can be severe, which may lead to low birth weight or preterm birth. Some women with gestational hypertension do go on to develop preeclampsia.
  • Chronic hypertension is high blood pressure that started before the 20th week of pregnancy or before you became pregnant. Some women may have had it long before becoming pregnant, but didn't know it until they got their blood pressure checked at their prenatal visit. Sometimes chronic hypertension can also lead to preeclampsia.
  • Preeclampsia is a sudden increase in blood pressure after the 20th week of pregnancy. It usually happens in the last trimester. In rare cases, symptoms may not start until after delivery. This is called postpartum preeclampsia. Preeclampsia also includes signs of damage to some of your organs, such as your liver or kidney. The signs may include protein in the urine and very high blood pressure. Preeclampsia can be serious or even life-threatening for both you and your baby.
What causes preeclampsia?

The cause of preeclampsia is not known.

Who is at risk for preeclampsia?

You are at higher risk of preeclampsia if you

  • Had chronic high blood pressure or chronic kidney disease before pregnancy
  • Had high blood pressure or preeclampsia in a previous pregnancy
  • Have obesity
  • Are over age 40
  • Are pregnant with more than one baby
  • Are African American
  • Have a family history of preeclampsia
  • Have certain health conditions, such as diabetes, lupus, or thrombophilia (a disorder which raises your risk of blood clots)
  • Used in vitro fertilization, egg donation, or donor insemination
What problems can preeclampsia cause?

Preeclampsia can cause

  • Placental abruption, where the placenta separates from the uterus
  • Poor fetal growth, caused by a lack of nutrients and oxygen
  • Preterm birth
  • A low birth weight baby
  • Stillbirth
  • Damage to your kidneys, liver, brain, and other organ and blood systems
  • A higher risk of heart disease for you
  • Eclampsia, which happens when preeclampsia is severe enough to affect brain function, causing seizures or coma
  • HELLP syndrome, which happens when a woman with preeclampsia or eclampsia has damage to the liver and blood cells. It is rare, but very serious.
What are the symptoms of preeclampsia?

Possible symptoms of preeclampsia include

  • High blood pressure
  • Too much protein in your urine (called proteinuria)
  • Swelling in your face and hands. Your feet may also swell, but many women have swollen feet during pregnancy. So swollen feet by themselves may not be a sign of a problem.
  • Headache that does not go away
  • Vision problems, including blurred vision or seeing spots
  • Pain in your upper right abdomen
  • Trouble breathing
  • Eclampsia can also cause seizures, nausea and/or vomiting, and low urine output. If you go on to develop HELLP syndrome, you may also have bleeding or bruising easily, extreme fatigue, and liver failure.

    How is preeclampsia diagnosed?

    Your health care provider will check your blood pressure and urine at each prenatal visit. If your blood pressure reading is high (140/90 or higher), especially after the 20th week of pregnancy, your provider will likely want to run some tests. They may include blood tests other lab tests to look for extra protein in the urine as well as other symptoms.

    How is preeclampsia treated?

    Delivering the baby can often cure preeclampsia. When making a decision about treatment, your provider take into account several factors. They include how severe it is, how many weeks pregnant you are, and what the potential risks to you and your baby are:

    • If you are more than 37 weeks pregnant, your provider will likely want to deliver the baby.
    • If you are less than 37 weeks pregnant, your health care provider will closely monitor you and your baby. This includes blood and urine tests for you. Monitoring for the baby often involves ultrasound, heart rate monitoring, and checking on the baby's growth. You may need to take medicines, to control your blood pressure and to prevent seizures. Some women also get steroid injections, to help the baby's lungs mature faster. If the preeclampsia is severe, you provider may want you to deliver the baby early.

    The symptoms usually go away within 6 weeks of delivery. In rare cases, symptoms may not go away, or they may not start until after delivery (postpartum preeclampsia). This can be very serious, and it needs to be treated right away.

Check out the latest treatments for VISION BLURRED

VISION BLURRED treatment research studies

Penicillin clinical trials, surveys and public health registries


Find Drug Side Effect reports



Penicillin Side Effects

Rash (32)
Pain (26)
Hypersensitivity (23)
Pruritus (17)
Urticaria (16)
Toxic Epidermal Necrolysis (14)
Dyspnoea (14)
Oedema Peripheral (13)
Pyrexia (13)
Vomiting (13)
Chest Pain (12)
Deep Vein Thrombosis (12)
Anxiety (12)
Erythema (11)
Headache (11)
Nausea (11)
Diarrhoea (9)
Injury (9)
Emotional Distress (9)
Swelling Face (8)
Pulmonary Embolism (8)
Alanine Aminotransferase Increased (8)
Pain In Extremity (7)
Renal Failure Acute (7)
Malaise (7)
Abdominal Pain (7)
Stevens-johnson Syndrome (7)
Rash Maculo-papular (6)
Anaphylactic Reaction (6)
Skin Exfoliation (6)
Aspartate Aminotransferase Increased (6)
Swelling (6)
Dysphagia (6)
Weight Decreased (6)
Angioedema (5)
Abdominal Pain Upper (5)
Fear (5)
Blood Creatinine Increased (5)
Haemorrhage (5)
Throat Tightness (5)
Dizziness (5)
Chromaturia (5)
Rash Pruritic (5)
Restlessness (5)
Fatigue (5)
Decreased Appetite (5)
No Adverse Event (4)
Neutropenia (4)
Blood Alkaline Phosphatase Increased (4)
Nasopharyngitis (4)

➢ More


Common Meds

Abilify (10132)
Adderall (1304)
Amlodipine (6664)
Amoxicillin (4387)
Benadryl (1568)
Celebrex (12876 )
Celexa (1342)
Cialis (2975)
Cipro (8580)
Citalopram (7792)
Crestor (18839)
Cymbalta (14373)
Doxycycline (1757)
Effexor (7289)
Flexeril (435)
Flomax (2177)
Fluoxetine (4261)
Gabapentin (4593)
Hydrocodone (2469)
Ibuprofen (8222)
Lantus (10968)
Lexapro (3499)
Lipitor (17769)
Lisinopril (8919)
Lyrica (27148)
Medrol (650)
Mirena (41254)
Mobic (957)
Morphine (5356)
Naproxen (538)
Neurontin (6501)
Oxycodone (4438)
Pradaxa (13372)
Prednisone (5926)
Prilosec (2631)
Prozac (1954)
Seroquel (27216)
Simvastatin (8348)
Synthroid (4452)
Tamiflu (5585)
Topamax (3748)
Tramadol (5054)
Trazodone (1458)
Viagra (5394)
Vicodin (1153)
Wellbutrin (6324)
Xanax (2847)
Zocor (5718)
Zoloft(6792)
Zyrtec(1669)

Recent Reviews

After i took penicilin..my body all swolen

Bakpo kawe isap rokok sero xsedap ni..

CHEST PAIN WITH CHILLS

Diarrhea,

Does it affect your sexual drive?

Head ache, feeling like i am getting the flu, very tired, achey

Headache

I am weak and tired, head ekes, fewer.

I had penicillin for 3 days both in hospital by needle in my arm and orally once discharged from hospital. I was admitted for severe tonsillitus and found to have no real noticable side effects until the 2nd night where I was constantly tired yet was

I have been taking penycillin now for a week because of an infection leading to root canal. From the penycillin, I have experienced headaches, dizziness, vertigo type symptoms, body and muscle aches and cramping. Symptoms have increased as the days h

fROM THE DAY i GOT THE INJECTION aCLASTA, i AM FEELING GIDDY AND HAVE LOST MY VISION. w WHAT IS YOUR RESPONSIBILITY ABOUT THIS fROM THE DAY i GOT aCLASTA INJECTION, i AM FEELING

Blurred vision, giddiness,Tiredness,Swelling on feet and hands

M 23 of age.. And via consultant i am taking seroxat(20mg)... about two mouths ago..but still sharp headache occured daily n morning...plus my vision gets blurred n morning..don't nw why..its really annoying... Lik eithr its a medicn side effects o

can advagraf makke you look like you are pregnant? Can this drug affect your eye site--blurry vision

Started taking Bystolic 5mg on Thursday for tachycardia. Sunday, had blurred vision. (Was driving and it was so bad that the interstate signs were blurred!) Stopped medicine and called doctor on Monday. Tuesday, called back because nobody saw f

<b>Describe Your Seroxat Experience Here:</b>Stomach and wierd vision and feeling tired

I was given Celestene by a GP in Frace for bronchial problems/ashma - 4mg for 10 days. It gave me really irritated red skin with spots, overy sensitive skin to my face which tingled when touched, stomach problems and blured vision

<span style='color: #808080;'><b>My son complained of not being able to see to well so I took him to lenscrafters to check his vision since he wore glasses before and had lost them. No big deal I thought, anyway they took some t

<span style='color: #808080;'><b>What do You think about Vision impairment and blindness?</b>

45 Male on Enbrel 4 + years , My condition is all but gone and I really use no other meds now. Expect a dry cough , Poor night vision ,Memory loss ,and in some cases (345) amniesia. IHAVE noticed a difficulty in learning new&am

VISION BLURRED Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.
Rank Status Study
1 Recruiting Oral Penicillin and Penicillin Levels in Venous Umbilical Cord Blood
Condition: Group B Streptococcus
Intervention: Drug: oral Penicillin V
Outcome Measures: The level of antibiotics in the umbilical vein cord blood of newborn infants after the administration of Penicillin orally while in labor.;   Compare levels of Penicillin in the umbilical cord blood of women who received oral Penicillin to the levels of women who received intravenous Penicillin in labor. Comparisons will be done through literature only.
2 Recruiting The Diagnosis of Penicillin/AminoPenicillin Allergy in Thailand
Conditions: Penicillin Allergy;   AminoPenicillin Allergy
Intervention:
Outcome Measures: The true prevalence of Penicillin/aminoPenicillin allergy;   The diagnostic values of currently used skin test reagents and drug-specific IgE measurement
3 Recruiting Perioperative Antibiotic Choices for Surgical Prophylaxis in Penicillin-allergic Pediatric Patients
Condition: Penicillin Allergy
Intervention: Drug: Antibiotic
Outcome Measure: Number of subjects with antibiotic related adverse event
4 Not yet recruiting Antibiotic Treatment and Intravenous Immunoglobulin Trial for PANDAS
Condition: Pandas
Interventions: Drug: Sertraline+Antibiotic (Penicillin/azithromycin);   Drug: Sertraline+placebo;   Biological: IVIG
Outcome Measures: The improvement of OC/tic symptoms will be superior in patients treated with SSRI+AB and in case with IVIG, compared with those treated with SSRI+placebo, as assessed by the YBOCS/YGTSS;   The degree of treatment response is expected to correlate with the percentage reduction in antibodies titers following IVIG administration;   The degree of treatment response is also expected to correlate with decreased inflammation in specific regions of the brain, as demonstrated by macroscopic changes and microstructural alterations on MRI and serum and CSF cytokines and chemokines
5 Recruiting A Comparative Evaluation of the Safety and Efficacy of Daptomycin Versus Standard of Care in Pediatric Subjects Two - Seventeen Years of Age With Bacteremia Caused by Staphylococcus Aureus
Condition: Bacteremia
Interventions: Drug: Daptomycin;   Drug: Comparator (Vancomycin, Semi-synthetic Penicillin, First-generation cephalosporins, Clindamycin)
Outcome Measures: Safety of daptomycin measured by the incidence of treatment-emergent adverse events, vital signs, echocardiogram (if performed) and clinical laboratory tests, use of concomitant medications,physical and neurological exam results.;   Efficacy of daptomycin will be based on Investigator's assessment of clinical response (cure, improved, failure or non-evaluable) at the Test of Cure (TOC) visit.
6 Not yet recruiting Patients Response to Early Switch To Oral:Osteomyelitis Study
Condition: Osteomyelitis
Interventions: Drug: oral antibiotics;   Procedure: intravenous antibiotics
Outcome Measures: Clinical Failures;   Evaluation of adverse events related to the use of antibiotics;   Cost of care from the hospital perspective
7 Unknown  Intravenous Immunoglobulins as Effective Treatment in Sydenham's Chorea
Conditions: Sydenham Chorea;   Post Streptococcal Movement Disorder
Interventions: Biological: Intravenous immunoglobulin;   Drug: standard interventions Penicillin VK and haloperidol
Outcome Measures: improved scores on the sydenham chorea assessment charts;   improved quality of life
8 Recruiting Neonatal and Paediatric Pharmacokinetics of Antimicrobials Study
Condition: Paediatric Antimicrobial Pharmacokinetics
Intervention:
Outcome Measure: The pharmacokinetic parameters of drug clearance and volume of distribution for each Penicillin.
9 Recruiting The Amputation Surgical Site Infection Trial (ASSIT)
Conditions: Wound Infection;   Amputation Wound
Interventions: Drug: Co-amoxiclav;   Drug: Iodine;   Drug: Metronidazole;   Drug: Chlorhexidine;   Drug: Teicoplanin;   Drug: Clindamycin
Outcome Measures: Surgical Site Infection;   Impact of different skin preparations on infection rates;   Rate of re-intervention;   Mortality;   Satisfactory healing rates;   Quality of life;   Resource use;   • Rate of C. Diff., MSSA (Methicillin Sensitive Staphylococcus Aureus), MRSA (Methicillin Resistant Staphylococcus Aureus) infection;   Mobility;   Pain Control
10 Recruiting The Role of Antibiotics in Full Thickness Skin Graft Survival for Facial Reconstructive Surgery
Condition: Facial Defect
Intervention: Drug: cephalexin
Outcome Measures: Graft failure rate;   Percentage surface area of graft failure
11 Unknown  The Effectiveness of Probiotics for the Therapy of Acute Pharyngotonsillitis in Adult Patients
Condition: Throat Pain
Interventions: Drug: Placebo;   Drug: Probiotics
Outcome Measures: period of disease;   analysis
12 Recruiting Extended Open Challenge in Patients With a History of Drug Eruption Following Beta-lactam Treatment
Condition: Beta-lactam Allergy
Intervention: Drug: Beta-lactam oral challenge
Outcome Measure: The safety of a 5-day oral challenge in patients with suspected beta-lactam allergy
13 Not yet recruiting Mortality Reduction After Oral Azithromycin: Morbidity Study
Condition: Childhood Mortality
Interventions: Drug: Azithromycin;   Drug: Placebo
Outcome Measures: Presence of malaria parasites on thick blood smear in children 1-60 months;   Fraction of isolates of pneumococcus exhibiting macrolide resistance by nasopharyngeal swabs in children 1-60 months;   Fraction of isolates of Staphylococcus aureus exhibiting macrolide resistance by nasal swabs in children 1-60 months;   Fraction of isolates of Streptococcus pyogenes exhibiting macrolide resistance by oropharyngeal swabs in children 1-60 months;   Evidence of E. coli macrolide resistance in stool specimens in children 1-60 months;   Fraction of conjunctival swabs yielding ocular chlamydia in children 1-60 months;   Height over time in children aged 1-60 months;   Presence of malaria gametocytes, and density of malaria parasites and gametocytes, in children 1-60 months;   Rates of malaria parasitemia among children 1-59.9 months.;   Hemoglobin concentration and presence of anemia (hemoglobin <11 g/dL) in children 1-60 months;   Nasopharyngeal pneumococcal macrolide resistance in individuals 7-12 years;   Nasopharyngeal pneumococcal macrolide resistance in children aged 1-60 months seen in local health clinics for a respiratory complaint;   Rates of acute respiratory illness among children 1-59.9 months.;   Carriage rates and proportions of S. pneumoniae isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months.;   Carriage rates and proportions of S. pneumoniae isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months hospitalized for pneumonia and diarrhea.;   Presence of the trachoma grades "follicular trachoma" (TF) and "intense inflammatory trachoma" (TI), as defined by the WHO simplified grading system, in children 1-60 months;   Trachoma infection and antibody status in children (1-60 months);   Rates of diarrhea among children 1-59.9 months.;   Carriage rates and proportions E. coli isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months;   Carriage rates and proportions of E. coli isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months hospitalized for pneumonia and diarrhea.;   Studies of intestinal permeability and inflammation, microbial translocation, and immune activation assessed through venous sampling of children 6 months;   Studies of intestinal permeability and inflammation, microbial translocation, and immune activation assessed through urine samples for L:M ratios of children 6 months;   Studies of intestinal permeability and inflammation, microbial translocation, and immune activation assessed through stool (fecal neopterin) of children 6 months;   Nasopharyngeal methicillin-resistant Staphylococcus aureus in children 1-60 months;   Carriage rates and proportions of S. aureus isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months.;   Carriage rates and proportions of S. aureus isolates resistant to macrolides and to antibiotics commonly used to treat pediatric infections among children 1-59.9 months hospitalized for pneumonia and diarrhea.;   Nasopharyngeal pneumococcal resistance to Penicillin and clindamycin in children 1-60 months;   Nasopharyngeal pneumococcal macrolide resistance determinants (ermB and mefA), serotype, and multilocus sequence type in children 1-60 months;   Oropharyngeal Streptococcus pyogenes macrolide resistance to Penicillin and clindamycin in children 1-60 months;   Oropharyngeal Streptococcus pyogenes macrolide resistance determinants (mefA, ermB, ermTR) in children 1-60 months;   Microbial diversity in the conjunctival, nasopharyngeal, nasal, oropharyngeal, and intestinal microbiomes of children aged 1-60 months;   Serology for exposure to exotic pathogens cross sectional sample of children aged 1-60 months;   Knee-heel length and head circumference over time in children aged 1-60 months;   Commensal and diarrheagenic E. coli carriage in stool of children aged 1-60 months
14 Recruiting A Trial Comparing Two Modalities of Prophylactic Nutritional Support During Treatment for Head and Neck Cancer
Condition: Head and Neck Neoplasms
Interventions: Procedure: percutaneous endoscopic gastrostomy tube placement;   Procedure: nasogastric tube placement
Outcome Measures: Nutritional Status;   Quality of Life + Mental/Emotional health;   Cost of care;   Clinical Complications;   Nutritional status
15 Unknown  Study to Proof the Clinical and Bacteriological Non-inferiority of Ampicillin/Amoxicillin Versus Moxifloxacin in Hospitalized Patients With Non-severe Community-acquired Pneumonia
Condition: Community Acquired Pneumonia
Interventions: Drug: Moxifloxacin;   Drug: Ampicillin;Amoxicillin
Outcome Measures: Proof of the clinical non inferiority by the cure rate at the treatment of a Pneumonia at the therapy end (round 3: Day 7 to 10) with a standard Penicillin in a high dosage;   clinical cure rate;   bacteriological effectiveness on patients and seed level;   bacteriological sensitivity into-vitro;   time up to the drug-switch;   time until the dismissal of the patients necessity of the gift of additional antibacterial drug;   cost reduction of the antibiotic-therapy and the complete treatment;   assessment of the effectiveness by the investigator
16 Recruiting Levofloxacin in Preventing Infection in Young Patients With Acute Leukemia Receiving Chemotherapy or Undergoing Stem Cell Transplantation
Conditions: Acute Leukemias of Ambiguous Lineage;   Bacterial Infection;   Diarrhea;   Fungal Infection;   Musculoskeletal Complications;   Neutropenia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Secondary Acute Myeloid Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
Intervention: Drug: levofloxacin
Outcome Measures: Occurrence of at least 1 episode of true bacteremia among AL and HSCT subjects, respectively;   Susceptibility of E. coli, K. pneumoniae, and P. aeruginosa to cefepime, imipenem, and levofloxacin;   Susceptibility of S. mitis to cefepime, levofloxacin, and Penicillin;   Presence of carbapenem-resistant Enterobacteriaceae;   Duration of parenteral antibiotic administration;   Incidence of febrile neutropenia, severe infection, and death from bacterial infection;   Incidence of severe infection;   Incidence of death from bacterial infection;   Incidence of CDAD, defined as a positive C. difficile toxin assay result and diarrhea, CTCAE version 4, grade 2 and higher
17 Recruiting The Effects of Modified Ultrafiltration on Vancomycin Levels During Cardiopulmonary Bypass in Cardiac Surgery
Condition: Vancomycin Concentration
Intervention: Other: Vancomycin concentrations
Outcome Measure: Circulating vancomycin concentration
18 Recruiting Multicenter Pilot Study Evaluating the Immunogenicity of an Innovative Pneumococcal Vaccination Strategy in Splenectomized Adults
Condition: Splenectomized Patients
Intervention: Biological: Prime-boost pneumococcal immunization
Outcome Measures: Proportion of subjects responsive to 9 of the 13 serotypes common (serotypes 1, 3, 6A, 7F, 9V, 14, 19A, 19F, 23F).;   IgG dosage;   ELISA dosages;   Identification of predictive factors for immunogenicity;   Percentage of patients presenting local or systemic reactions post-immunization;   Evaluation of severe infectious episode;   OPA dosages
19 Not yet recruiting Prophylactic Antibiotics for Manual Removal of Retained Placenta in Vaginal Birth: a Randomized Controlled Trial
Condition: Endometritis
Interventions: Drug: Antibiotic prophylaxis;   Drug: Ampicillin;   Drug: Gentamycin;   Drug: Clindamycin
Outcome Measures: Endometritis rate;   Puerperal fever
20 Recruiting Assessment of the Optimal Dosing of Piperacillin-tazobactam in Intensive Care Unit Patients: Extended Versus Continuous Infusion
Condition: Infectious Disease
Interventions: Drug: piperacillin continuous infusion;   Drug: piperacillin extended infusion
Outcome Measures: pharmacokinetics of piperacillin continuous infusion compared to piperacillin extended infusion;   95% probability of target attainment (PTA95) versus MIC of different organisms.